Form D · Biotechnology
Spotlight Therapeutics, Inc.
Hayward, CA · CIK 0001726495
Offering snapshot reported Jan 5, 2022 · SEC filing
- Reported sold
- $32.2M Offering amount: $65M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 10, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 5, 2022 | Initial | $32,204,975 | No comparison | 11 | SEC filing |
| Mar 4, 2021 | Initial | $15,189,998 | No comparison | 15 | SEC filing |
| Sep 25, 2019 | Initial | $6,899,997 | No comparison | 6 | SEC filing |
| Jan 3, 2018 | Initial | $7,266,667 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-427880
Source: Form D, filed Jan 5, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Blake Byers | Director |
| Jacob Corn | Director |
| Mary Haak Frendscho | Executive |
| Patrick David Hsu | Director |
| Alexander Marson | Director |
| Krishna Yeshwant | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3953 Point Eden Way
Hayward, CA, 94545
Hayward, CA, 94545